MCID: MNC007
MIFTS: 54

Monocytic Leukemia

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Monocytic Leukemia

MalaCards integrated aliases for Monocytic Leukemia:

Name: Monocytic Leukemia 12 52 14 69
M5b Acute Differentiated Monocytic Leukemia 69
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD10 33 C93.Z C93.Z0 C93
ICD9CM 35 206.8
UMLS 69 C0153903

Summaries for Monocytic Leukemia

MalaCards based summary : Monocytic Leukemia, also known as m5b acute differentiated monocytic leukemia, is related to lymphoma and scabies. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cytarabine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, monocytes and bone, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Wikipedia : 72 Monocytic leukemia is a type of myeloid leukemia characterized by a dominance of monocytes in the... more...

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Acute Monocytic Leukemia Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 301)
id Related Disease Score Top Affiliating Genes
1 lymphoma 29.6 IFNG IL1B IL6 TNF
2 scabies 27.0 CXCL8 IFNG IL1B IL6 ITGAM TNF
3 reticulosarcoma 21.4 CASP3 CD14 CSF1 CSF2 CXCL8 F3
4 acute monocytic leukemia 12.5
5 adult acute monocytic leukemia 12.3
6 chronic monocytic leukemia 12.1
7 aleukemic monocytic leukemia cutis 12.1
8 subacute monocytic leukemia 12.0
9 acute monoblastic leukemia 11.4
10 leukemia 10.8
11 smarca4-deficient sarcoma of thorax 10.6 IL6 TNF
12 adult acute lymphocytic leukemia 10.5 KAT6A KIAA0100 KMT2A MYH7B
13 ulcerative colitis 10.4 CASP3 IL6 TNF
14 aortic arch interruption 10.4 IL6 TNF
15 psychologic dyspareunia 10.4 CASP3 IFNG TNF
16 lymphocytic colitis 10.4 IFNG IL6 TNF
17 cyclosporiasis 10.4 IFNG IL6 TNF
18 hemophagocytic lymphohistiocytosis 10.3 IFNG IL6 TNF
19 autoimmune polyglandular syndrome type 3 10.3 IFNG PPARG TNF
20 conduct disorder 10.3 IFNG IL6 TNF
21 reardon wilson cavanagh syndrome 10.3 IFNG IL6 TNF
22 cutaneous leishmaniasis 10.3 IL6 TNF
23 orbital osteomyelitis 10.3 IFNG IL6 TNF
24 disease of mental health 10.3 IFNG IL6 TNF
25 abnormal retinal correspondence 10.3 IFNG IL6 TNF
26 extrahepatic bile duct adenocarcinoma 10.3 IFNG IL6 TNF
27 melioidosis 10.3 IFNG IL6 TNF
28 tabatznik syndrome 10.3 IL1B TNF
29 cornea cancer 10.3 IFNG IL6 TNF
30 heart sarcoma 10.3 IFNG IL6 TNF
31 gastric ulcer 10.3 IFNG IL6 TNF
32 acute interstitial pneumonia 10.3 IFNG IL6 TNF
33 ethmoid sinus cancer 10.3 IFNG IL1B JUN
34 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 10.2 F3 IFNG IL6
35 scrotal carcinoma 10.2 IL1B IL6 TNF
36 sternal cleft 10.2 IFNG IL1B TNF
37 upper gum cancer 10.2 IL1B IL6 TNF
38 bipolar i disorder 10.2 IL1B IL6 TNF
39 tinea favosa 10.2 IL1B IL6 TNF
40 central nervous system leiomyosarcoma 10.2 IL1B IL6 TNF
41 indolent myeloma 10.2 IL1B IL6 TNF
42 ampulla of vater neoplasm 10.2 IL1B IL6 TNF
43 brucella canis brucellosis 10.2 IL1B IL6 TNF
44 foodborne botulism 10.2 IL1B IL6 TNF
45 noma 10.2 IL1B IL6 TNF
46 human monocytic ehrlichiosis 10.2 IL1B IL6 TNF
47 high pressure neurological syndrome 10.2 IL1B IL6 TNF
48 ostertagiasis 10.2 IL1B IL6 TNF
49 osmotic diarrhea 10.2 IL1B IL6 TNF
50 mikulicz disease 10.2 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CASP3 CSF2 CXCL8 TNF

MGI Mouse Phenotypes related to Monocytic Leukemia:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 CASP3 CD14 CSF1 CSF2 F3 IFNG
2 cardiovascular system MP:0005385 10.37 IFNG IL1B IL6 JUN KAT6A KMT2A
3 homeostasis/metabolism MP:0005376 10.37 IL6 ITGAM JUN KAT6A KMT2A PPARG
4 cellular MP:0005384 10.36 CASP3 CSF1 CSF2 F3 IL6 ITGAM
5 immune system MP:0005387 10.36 CSF2 F3 IFNG IL1B IL6 ITGAM
6 behavior/neurological MP:0005386 10.34 CASP3 CSF1 CSF2 F3 IFNG IL6
7 growth/size/body region MP:0005378 10.33 CASP3 CD14 CSF1 CSF2 F3 IFNG
8 integument MP:0010771 10.27 CASP3 CSF1 CSF2 F3 IFNG IL1B
9 mortality/aging MP:0010768 10.27 CASP3 CD14 CSF1 CSF2 F3 IFNG
10 endocrine/exocrine gland MP:0005379 10.21 CASP3 CSF1 CSF2 IFNG IL6 JUN
11 nervous system MP:0003631 10.18 CASP3 CSF1 CSF2 F3 IFNG IL1B
12 embryo MP:0005380 10.17 CSF2 F3 IFNG JUN KAT6A KMT2A
13 craniofacial MP:0005382 10.12 CASP3 CSF1 CSF2 IFNG KAT6A KMT2A
14 liver/biliary system MP:0005370 10.08 CSF1 IFNG IL6 JUN KAT6A KMT2A
15 muscle MP:0005369 10.03 CASP3 CSF1 F3 IFNG IL6 KMT2A
16 neoplasm MP:0002006 10.01 CSF2 F3 IFNG IL1B IL6 KMT2A
17 reproductive system MP:0005389 9.91 CASP3 CSF1 CSF2 IFNG IL6 KAT6A
18 no phenotypic analysis MP:0003012 9.87 CASP3 CSF1 IFNG JUN KMT2A PPARG
19 respiratory system MP:0005388 9.81 CASP3 CD14 CSF1 CSF2 F3 IFNG
20 skeleton MP:0005390 9.73 CASP3 CD14 CSF1 CSF2 IFNG IL1B
21 vision/eye MP:0005391 9.23 CSF1 F3 IFNG IL6 JUN PPARG

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
4
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
5
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
7
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
8
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
9
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
10
Mesna Approved Phase 3 3375-50-6 598
11
Amsacrine Approved Phase 3 51264-14-3 2179
12
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
13
Clofarabine Approved, Investigational Phase 2, Phase 3, Phase 1 123318-82-1 119182
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
15
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
17
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
18
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
19
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Hydroxyurea Approved Phase 3 127-07-1 3657
21
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
22
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
23
Azacitidine Approved, Investigational Phase 2, Phase 3, Phase 1 320-67-2 9444
24
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
25
Carmustine Approved Phase 3 154-93-8 2578
26
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
27
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
28
Fluconazole Approved Phase 3 86386-73-4 3365
29
Cyproheptadine Approved Phase 3 129-03-3 2913
30
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
31
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
34
Butyric Acid Experimental Phase 3 107-92-6 264
35
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
36 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
37 Vaccines Phase 3,Phase 1
38 Analgesics Phase 3,Phase 2,Phase 1
39 Antibodies Phase 3,Phase 2
40 Antibodies, Monoclonal Phase 3,Phase 2
41 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
42 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 3,Phase 2,Phase 1,Early Phase 1
46 Etoposide phosphate Phase 3,Phase 2,Phase 1
47 Immunoglobulins Phase 3,Phase 2
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 193)

id Name Status NCT ID Phase Drugs
1 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
2 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
3 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
4 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
5 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
6 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
12 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
13 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
14 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
15 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
16 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
17 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
18 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
19 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
20 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
22 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
23 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
24 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
25 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
26 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
27 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
28 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
29 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
30 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
31 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
33 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
34 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
36 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
37 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
38 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
39 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
40 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
41 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
42 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
43 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
44 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
45 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
46 S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00093418 Phase 2 tipifarnib
47 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
48 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
50 Vorinostat in Treating Patients With Acute Myeloid Leukemia Completed NCT00305773 Phase 2 vorinostat;vorinostat

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

39
Myeloid, Monocytes, Bone, Bone Marrow, Skin, Lung, Prostate

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 527)
id Title Authors Year
1
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. ( 27859216 )
2017
2
The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-I_B Signaling. ( 28832545 )
2017
3
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. ( 28713913 )
2017
4
C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia. ( 28693135 )
2017
5
Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway. ( 28912858 )
2017
6
5a89azaa892'a89deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2a89CCR2a89ERK signaling pathway. ( 28627644 )
2017
7
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. ( 28634616 )
2017
8
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. ( 28108519 )
2017
9
Cutaneous presentation preceding acute monocytic leukemia: A CARE-compliant article. ( 28272239 )
2017
10
Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia. ( 28625614 )
2017
11
Duplication of subtelomeric regions in an adult with acute monocytic leukemia with an acquired jumping translocation involving 3q13.31-qter. ( 28725672 )
2017
12
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. ( 28270496 )
2017
13
Knockdown of p54nrb inhibits migration, invasion and TNF-I+ release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
14
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
15
Antioxidation and antiproliferation of ethanol extracts from edible mushrooms against U937 human monocytic leukemia cells. ( 27976050 )
2016
16
A Wnt pathway activator induces apoptosis and cell death in mouse monocytic leukemia cells. ( 27623760 )
2016
17
Acute Monocytic Leukemia Masquerading BehAset's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
18
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
19
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
20
Hypoxia inducible factor-1a regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
21
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
22
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2016
23
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
24
Spurious Thrombocytosis Caused by Tumor Cell Lysis in a Patient with Acute Monocytic Leukemia. ( 28164618 )
2016
25
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
26
Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. ( 26125761 )
2015
27
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2015
28
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
29
Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq. ( 26582014 )
2015
30
Curcumin induces apoptosis and suppresses invasion through MAPK and MMP signaling in human monocytic leukemia SHI-1 cells. ( 26134921 )
2015
31
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. ( 26136223 )
2015
32
Hypomethylating agents as bridging therapy before allogeneic hematopoietic stem cell transplant in patients with chronic myelo-monocytic leukemia (CMML) ? ( 26576835 )
2015
33
Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. ( 25546124 )
2015
34
Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. ( 25973292 )
2015
35
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
36
Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. ( 24619942 )
2014
37
Momilactone B induces apoptosis and G1 arrest of the cell cycle in human monocytic leukemia U937 cells through downregulation of pRB phosphorylation and induction of the cyclin-dependent kinase inhibitor p21Waf1/Cip1. ( 24503697 )
2014
38
Posterior reversible encephalopathy syndrome following acute pancreatitis during chemotherapy for acute monocytic leukemia. ( 24881921 )
2014
39
RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. ( 24652966 )
2014
40
Severe aplastic anemia preceding acute monocytic leukemia in an adult with acquired trisomy 21: A case report. ( 24396488 )
2014
41
Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. ( 25447656 )
2014
42
Modulation of monocytic leukemia cell function and survival by high gradient magnetic fields and mathematical modeling studies. ( 24439412 )
2014
43
The need for continuing chemotherapy for leukemic cell lysis pneumopathy in patients with acute myelomonocytic/monocytic leukemia. ( 23728559 )
2013
44
Regulated cellular exposure to non-thermal plasma allows preferentially directed apoptosis in acute monocytic leukemia cells. ( 23400198 )
2013
45
Antiproliferative activities of lesser galangal (Alpinia officinarum Hance Jam1), turmeric (Curcuma longa L.), and ginger (Zingiber officinale Rosc.) against acute monocytic leukemia. ( 23819642 )
2013
46
Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia. ( 23995854 )
2013
47
Reverse signaling from LIGHT promotes pro-inflammatory responses in the human monocytic leukemia cell line, THP-1. ( 24044961 )
2013
48
Bryostatin 5 induces apoptosis in acute monocytic leukemia cells by activating PUMA and caspases. ( 24036350 )
2013
49
In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. ( 23823657 )
2013
50
Leukemia cutis in a patient with acute monocytic leukemia diagnosed simultaneously with hepatocellular carcinoma: A case study. ( 24179516 )
2013

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 88)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
2
Show member pathways
13.92 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
3
Show member pathways
13.75 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
4
Show member pathways
13.48 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
5
Show member pathways
13.46 CASP3 CSF1 CSF2 CXCL8 IFNG IL1B
6
Show member pathways
13.41 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
7
Show member pathways
13.09 CD14 CXCL8 F3 IL1B IL6 JUN
8
Show member pathways
12.99 CD14 CXCL8 IFNG IL1B IL6 JUN
9
Show member pathways
12.94 CASP3 CXCL8 IFNG IL1B IL6 TNF
10
Show member pathways
12.91 CASP3 CXCL8 IFNG IL1B IL6 JUN
11
Show member pathways
12.79 CXCL8 IFNG IL1B IL6 TNF
12 12.78 CASP3 CD14 IL1B JUN TNF
13 12.74 CASP3 CXCL8 IL6 JUN PPARG
14
Show member pathways
12.74 CASP3 IFNG IL1B JUN TNF
15
Show member pathways
12.69 CASP3 CD14 IL1B JUN TNF
16
Show member pathways
12.67 IFNG IL1B IL6 JUN TNF
17
Show member pathways
12.67 CD14 IFNG IL1B IL6 TNF
18
Show member pathways
12.63 CASP3 CD14 CSF2 IL6 ITGAM JUN
19
Show member pathways
12.61 CASP3 CSF2 IFNG JUN TNF
20
Show member pathways
12.56 CSF2 IFNG IL1B IL6 JUN TNF
21 12.47 CSF2 IL6 JUN TNF
22
Show member pathways
12.47 CASP3 CSF2 CXCL8 IFNG IL1B IL6
23
Show member pathways
12.41 CD14 CXCL8 IFNG IL1B IL6 JUN
24
Show member pathways
12.4 CASP3 IFNG IL1B ITGAM JUN TNF
25 12.38 CD14 CSF2 CXCL8 IL6 ITGAM KMT2A
27 12.37 CASP3 CD14 IFNG IL1B IL6 ITGAM
28 12.32 CASP3 CXCL8 IL1B IL6 JUN TNF
29
Show member pathways
12.32 CD14 CXCL8 IFNG IL1B IL6 JUN
30
Show member pathways
12.28 CXCL8 IFNG IL1B IL6 TNF
31 12.26 CASP3 IFNG IL6 TNF
32 12.21 CSF1 IFNG IL1B JUN PPARG TNF
33 12.18 IFNG IL1B JUN TNF
34 12.17 CASP3 CXCL8 IFNG IL1B IL6 TNF
35 12.16 CD14 CSF1 CSF2 IFNG IL6 ITGAM
36 12.12 CXCL8 IL1B IL6 ITGAM TNF
37 12.09 CXCL8 IFNG IL1B IL6 JUN KMT2A
38 12.09 CASP3 CSF1 CSF2 IL1B IL6 JUN
39
Show member pathways
12.08 IFNG IL1B IL6 JUN TNF
40 12.03 CASP3 CXCL8 F3 IL1B IL6 JUN
41 12.01 CD14 CSF1 CSF2 IL1B IL6 ITGAM
42 12 CD14 IL6 ITGAM PPARG
43 12 CD14 CXCL8 IL1B TNF
44
Show member pathways
11.99 CD14 CSF2 CXCL8 IL6
45
Show member pathways
11.95 IFNG IL1B IL6
46 11.95 CSF2 CXCL8 IFNG IL6 JUN
47 11.94 CD14 CSF2 CXCL8 IFNG IL1B IL6
48 11.91 IFNG IL1B ITGAM TNF
49
Show member pathways
11.86 CASP3 CXCL8 JUN
50
Show member pathways
11.86 CASP3 CSF2 CXCL8 IFNG JUN PPARG

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CD14 CSF1 CSF2 CXCL8 F3 IFNG
2 extracellular space GO:0005615 9.32 CD14 CSF1 CSF2 CXCL8 F3 IFNG
3 MOZ/MORF histone acetyltransferase complex GO:0070776 9.26 KAT6A KAT6B
4 external side of plasma membrane GO:0009897 9.26 CD14 IFNG IL6 TNF

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 CSF1 CSF2 IFNG IL6 JUN
2 inflammatory response GO:0006954 9.99 CD14 CSF1 CXCL8 IL1B IL6 TNF
3 positive regulation of gene expression GO:0010628 9.95 CSF1 CSF2 IFNG IL1B IL6 TNF
4 response to organic cyclic compound GO:0014070 9.92 CASP3 IL6 JUN PPARG
5 positive regulation of protein kinase B signaling GO:0051897 9.89 F3 IL6 TNF
6 response to lipopolysaccharide GO:0032496 9.89 CASP3 CD14 IL1B IL6 JUN
7 cellular response to organic cyclic compound GO:0071407 9.88 CASP3 IL1B TNF
8 apoptotic signaling pathway GO:0097190 9.88 CASP3 CD14 TNF
9 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.88 IL1B IL6 PPARG TNF
10 positive regulation of apoptotic process GO:0043065 9.88 CASP3 IFNG IL6 JUN PPARG TNF
11 response to glucocorticoid GO:0051384 9.87 CASP3 IL6 TNF
12 regulation of insulin secretion GO:0050796 9.86 IFNG IL1B TNF
13 neutrophil chemotaxis GO:0030593 9.86 CXCL8 IFNG IL1B
14 response to organic substance GO:0010033 9.86 CASP3 JUN PPARG TNF
15 response to mechanical stimulus GO:0009612 9.85 IL6 JUN PPARG
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 CSF2 IFNG IL6
17 positive regulation of T cell proliferation GO:0042102 9.85 IFNG IL1B IL6
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 IL6 JUN TNF
19 humoral immune response GO:0006959 9.84 IFNG IL6 TNF
20 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.83 CASP3 F3 PPARG TNF
21 positive regulation of interleukin-6 production GO:0032755 9.82 IL1B IL6 TNF
22 positive regulation of interferon-gamma production GO:0032729 9.82 CD14 IL1B TNF
23 positive regulation of DNA replication GO:0045740 9.81 CSF2 IL6 JUN
24 negative regulation of cell proliferation GO:0008285 9.8 CXCL8 IFNG IL1B IL6 JUN KMT2A
25 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.79 CSF2 IL1B TNF
26 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 CD14 IL1B TNF
27 negative regulation of collagen biosynthetic process GO:0032966 9.72 IL6 PPARG
28 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.72 IL1B TNF
29 response to molecule of bacterial origin GO:0002237 9.72 CD14 CXCL8
30 positive regulation of osteoclast differentiation GO:0045672 9.72 CSF1 IFNG TNF
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL1B TNF
32 positive regulation of protein import into nucleus, translocation GO:0033160 9.71 IFNG IL6
33 positive regulation of podosome assembly GO:0071803 9.71 CSF2 TNF
34 response to caffeine GO:0031000 9.71 IL6 PPARG
35 negative regulation of lipid storage GO:0010888 9.7 IL6 TNF
36 positive regulation of monocyte differentiation GO:0045657 9.7 CSF1 JUN
37 regulation of defense response to virus by host GO:0050691 9.69 IFNG IL1B
38 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.68 IFNG IL1B
39 regulation of establishment of endothelial barrier GO:1903140 9.67 IL1B TNF
40 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.66 IL6 TNF
41 positive regulation of interleukin-23 production GO:0032747 9.65 CSF2 IFNG
42 positive regulation of fever generation GO:0031622 9.65 IL1B TNF
43 sequestering of triglyceride GO:0030730 9.63 IL1B TNF
44 monocyte differentiation GO:0030224 9.63 CSF2 JUN PPARG
45 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 IFNG IL1B IL6 TNF
46 neutrophil apoptotic process GO:0001781 9.61 IFNG IL6
47 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IFNG IL1B TNF
48 positive regulation of vitamin D biosynthetic process GO:0060557 9.57 IFNG TNF
49 positive regulation of chemokine biosynthetic process GO:0045080 9.54 IFNG IL1B TNF
50 cellular response to lipopolysaccharide GO:0071222 9.43 CD14 CSF2 CXCL8 IFNG IL6 TNF

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.26 JUN KMT2A PPARG TNF
2 cytokine activity GO:0005125 9.17 CSF1 CSF2 CXCL8 IFNG IL1B IL6
3 acetyltransferase activity GO:0016407 9.16 KAT6A KAT6B

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....